bluuebunny/crossref_metadata_2025 huggingface dataset:
Tables S2_3_4 from Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer
Authors: Flores-Morales Amilcar , Bergmann Tobias B. , Lavallee Charlotte , Batth Tanveer S. , Lin Dong , Lerdrup Mads , Friis Stine , Bartels Anette , Kristensen Gitte , Krzyzanowska Agnieszka , Xue Hui , Fazli Ladan , Hansen Klaus H. , Røder Martin A. , Brasso Klaus , Moreira José M. , Bjartell Anders , Wang Yuzhuo , Olsen Jesper V. , Collins Colin C. , Iglesias-Gato Diego
Published: April 2023

Tables S2_3_4
Supplementary Data 2 from A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Authors: Ghobrial Irene M. , Liu Chia-Jen , Redd Robert A. , Perez Raymond P. , Baz Rachid , Zavidij Oksana , Sklavenitis-Pistofidis Romanos , Richardson Paul G. , Anderson Kenneth C. , Laubach Jacob , Henrick Patrick , Savell Alexandra , Reyes Kaitlen , Hornburg Kalvis , Chuma Stacey , Sabbatini Peter , Robbins Michael D. , Becker Pamela S.
Published: April 2023

The figures show that patients received 10 mg ulocuplumab could reach higher concentration peak and larger dose-corrected area under curve (both p < 0.001).
Supplementary Data from Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients
Authors: Duvvuri Umamaheswar , George Jonathan , Kim Seungwon , Alvarado Diego , Neumeister Veronique M. , Chenna Ahmed , Gedrich Richard , Hawthorne Thomas , LaVallee Theresa , Grandis Jennifer R. , Bauman Julie E.
Published: April 2023

Table S1. Pharmacokinetic Parameters Figure S1. Ki67 Expression by IHC. Figure S2: ErbB3 RNA and protein expression are significantly correlated. Figure S3. Statistical correlations between biomarker subsets.
Supplemental Figure S8 from Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination
Authors: Tu Yiming , Chen Zhenyao , Zhao Pengzhan , Sun Guangchi , Bao Zhongyuan , Chao Honglu , Fan Liang , Li Chong , You Yongping , Qu Yan , Chen Yun , Ji Jing
Published: April 2023

Supplemental Figure S8
Supplemental Figure S5 from Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination
Authors: Tu Yiming , Chen Zhenyao , Zhao Pengzhan , Sun Guangchi , Bao Zhongyuan , Chao Honglu , Fan Liang , Li Chong , You Yongping , Qu Yan , Chen Yun , Ji Jing
Published: April 2023

Supplemental Figure S5
Supplementary Table 4 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Authors: Keung Emily Z. , Burgess Melissa , Salazar Ruth , Parra Edwin R. , Rodrigues-Canales Jaime , Bolejack Vanessa , Van Tine Brian A. , Schuetze Scott M. , Attia Steven , Riedel Richard F. , Hu James , Okuno Scott H. , Priebat Dennis A. , Movva Sujana , Davis Lara E. , Reed Damon R. , Reuben Alexandre , Roland Christina L. , Reinke Denise , Lazar Alexander J. , Wang Wei-Lien , Wargo Jennifer A. , Tawbi Hussein A.
Published: April 2023

Comparison of tumor PD-L1 expression and tumor immune infiltrate between baseline tumor biopsies from responders and nonresponders (UPS/DDLPS only)
Supplemental Figure S4 from Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination
Authors: Tu Yiming , Chen Zhenyao , Zhao Pengzhan , Sun Guangchi , Bao Zhongyuan , Chao Honglu , Fan Liang , Li Chong , You Yongping , Qu Yan , Chen Yun , Ji Jing
Published: April 2023

Supplemental Figure S4
Supplemental Figure S10 from Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination
Authors: Tu Yiming , Chen Zhenyao , Zhao Pengzhan , Sun Guangchi , Bao Zhongyuan , Chao Honglu , Fan Liang , Li Chong , You Yongping , Qu Yan , Chen Yun , Ji Jing
Published: April 2023

Supplemental Figure S10
Supplementary Video S1 from Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models
Authors: Zhang Mo , Kobayashi Naoko , Zettlitz Kirstin A. , Kono Evelyn A. , Yamashiro Joyce M. , Tsai Wen-Ting K. , Jiang Ziyue K. , Tran Chau P. , Wang Chung , Guan Johnny , Wu Anna M. , Reiter Robert E.
Published: April 2023

Surgical resection of intramuscular 22Rv1-PSCA-Fluc tumors with real-time fluorescence guidance
Supplementary Table 4 from Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion
Authors: Ryu Daeun , Kim Seok Jin , Hong Yourae , Jo Areum , Kim Nayoung , Kim Hee-Jin , Lee Hae-Ock , Kim Kihyun , Park Woong-Yang
Published: April 2023

Multivariate analysis of overall survival
Supplementary Data from Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer
Authors: Saleh Anthony D. , Cheng Hui , Martin Scott E. , Si Han , Ormanoglu Pinar , Carlson Sophie , Clavijo Paul E. , Yang Xinping , Das Rita , Cornelius Shaleeka , Couper Jamie , Chepeha Douglas , Danilova Ludmila , Harris Thomas M. , Prystowsky Michael B. , Childs Geoffrey J. , Smith Richard V. , Robertson A. Gordon , Jones Steven J. M. , Cherniack Andrew D. , Kim Sang S. , Rait Antonina , Pirollo Kathleen F. , Chang Esther H. , Chen Zhong , Van Waes Carter
Published: April 2023

Supplementary Figures 1-9
Supplementary Materials and Methods from Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer
Authors: Nouri Mannan , Massah Shabnam , Caradec Josselin , Lubik Amy A. , Li Na , Truong Sarah , Lee Ahn R. , Fazli Ladan , Ramnarine Varune R. , Lovnicki Jessica M. , Moore Jackson , Wang Mike , Foo Jane , Gleave Martin E. , Hollier Brett G. , Nelson Colleen , Collins Colin , Dong Xuesen , Buttyan Ralph
Published: April 2023

Supplementary Materials and Methods with detailed methods and primer and antibody lists.
Figure S7 from Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer
Authors: Karasinska Joanna M. , Topham James T. , Kalloger Steve E. , Jang Gun Ho , Denroche Robert E. , Culibrk Luka , Williamson Laura M. , Wong Hui-Li , Lee Michael K.C. , O'Kane Grainne M. , Moore Richard A. , Mungall Andrew J. , Moore Malcolm J. , Warren Cassia , Metcalfe Andrew , Notta Faiyaz , Knox Jennifer J. , Gallinger Steven , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Renouf Daniel J. , Schaeffer David F.
Published: April 2023

Boxplots demonstrating expression values (z-score) for genes involved in amino acid catabolism (n=64), nucleotide metabolism (n=272) or the pentose phosphate pathway (n=100). P values were calculated using multiple pairwise Wilcoxon rank sum tests (two-tailed), and were subjected to Benjamini-Hochberg multiple test correction.
Supplementary Table S3. Safety Population - Grade {greater than or equal to} 3 Adverse Reactions from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
Authors: Jen Emily Y. , Xu Qing , Schetter Aaron , Przepiorka Donna , Shen Yuan Li , Roscoe Donna , Sridhara Rajeshwari , Deisseroth Albert , Philip Reena , Farrell Ann T. , Pazdur Richard
Published: April 2023

Grade >/= 3 AR
Figure S1 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Authors: Hall Peter E. , Lewis Rachel , Syed Nelofer , Shaffer Richard , Evanson Jane , Ellis Stephen , Williams Matthew , Feng Xiaoxing , Johnston Amanda , Thomson Jim A. , Harris Fiona P. , Jena Raj , Matys Tomasz , Jefferies Sarah , Smith Kate , Wu Bor-Wen , Bomalaski John S. , Crook Timothy , O'Neill Kevin , Paraskevopoulos Dimitris , Khadeir Ramsay S. , Sheaff Michael , Pacey Simon , Plowman Piers N. , Szlosarek Peter W.
Published: April 2023

ASS1 immunohistochemistry
Supplementary Tables from Primary Preclinical and Clinical Evaluation of 68Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Authors: Li Fei , Zhang Zhenzhong , Cai Jiong , Chen Xi , Zhou Ying , Ma Xiangyi , Dong Qingjian , Li Fang , Xi Ling
Published: April 2023

Supplementary Tables
Supplementary Fig S2 from Primary Preclinical and Clinical Evaluation of 68Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Authors: Li Fei , Zhang Zhenzhong , Cai Jiong , Chen Xi , Zhou Ying , Ma Xiangyi , Dong Qingjian , Li Fang , Xi Ling
Published: April 2023

The saturation binding curve using the LECs with 1-40 nM of 68Ga-DOTA-TMVP1.
Figure S1 from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma
Authors: Barry Wesley E. , Jackson Jeremy R. , Asuelime Grace E. , Wu Hong-Wei , Sun Jianping , Wan Zesheng , Malvar Jemily , Sheard Michael A. , Wang Larry , Seeger Robert C. , Kim Eugene S.
Published: April 2023

GD2 expression levels
Supplementary Table 2 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Table 2
Supplementary Table 1 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Table 1
Supplementary Figure 2 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Figure 2
Table S2 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Authors: Somaiah Neeta , Block Matthew S. , Kim Joseph W. , Shapiro Geoffrey I. , Do Khanh T. , Hwu Patrick , Eder Joseph P. , Jones Robin L. , Lu Hailing , ter Meulen Jan H. , Bohac Chet , Chen Michael , Hsu Frank J. , Gnjatic Sacha , Pollack Seth M.
Published: April 2023

Table S2 shows NY-ESO-1 expression levels at screening by tumor type.
Figure S1 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Authors: Somaiah Neeta , Block Matthew S. , Kim Joseph W. , Shapiro Geoffrey I. , Do Khanh T. , Hwu Patrick , Eder Joseph P. , Jones Robin L. , Lu Hailing , ter Meulen Jan H. , Bohac Chet , Chen Michael , Hsu Frank J. , Gnjatic Sacha , Pollack Seth M.
Published: April 2023

Figure S1 shows Kaplan-Meier curves for progression-free and overall survival in patients with sarcoma.
Supplementary Data from Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response
Authors: Payen Thomas , Oberstein Paul E. , Saharkhiz Niloufar , Palermo Carmine F. , Sastra Stephen A. , Han Yang , Nabavizadeh Alireza , Sagalovskiy Irina R. , Orelli Barbara , Rosario Vilma , Desrouilleres Deborah , Remotti Helen , Kluger Michael D. , Schrope Beth A. , Chabot John A. , Iuga Alina C. , Konofagou Elisa E. , Olive Kenneth P.
Published: April 2023

Supplementary Methods
Table S3 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Table S3: Treatment regimens of the Avatar patient derived xenograft models carrying the VEGFR2 WT and L840F genotypes.
Supplementary Table 1 tracked changes from Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors
Authors: Atrafi Florence , van Eerden Ruben A.G. , van Hylckama Vlieg Marte A.M , Oomen-de Hoop Esther , de Bruijn Peter , Lolkema Martijn P. , Moelker Adriaan , Rijcken Cristianne J. , Hanssen Rob , Sparreboom Alex , Eskens Ferry A.L.M. , Mathijssen Ron H.J. , Koolen Stijn L.W.
Published: April 2023

Supplementary Table 1 tracked changes
Supplementary Figure legend from Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors
Authors: Atrafi Florence , van Eerden Ruben A.G. , van Hylckama Vlieg Marte A.M , Oomen-de Hoop Esther , de Bruijn Peter , Lolkema Martijn P. , Moelker Adriaan , Rijcken Cristianne J. , Hanssen Rob , Sparreboom Alex , Eskens Ferry A.L.M. , Mathijssen Ron H.J. , Koolen Stijn L.W.
Published: April 2023

Supplementary Figure legend
Figure S1-9 from Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Authors: Liu Chao , Sadat Sayed H. , Ebisumoto Koji , Sakai Akihiro , Panuganti Bharat A. , Ren Shuling , Goto Yusuke , Haft Sunny , Fukusumi Takahito , Ando Mizuo , Saito Yuki , Guo Theresa , Tamayo Pablo , Yeerna Huwate , Kim William , Hubbard Jacqueline , Sharabi Andrew B. , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Figure S1: CNR1 and CNR2 affect the proliferation of HPV positive HNSCC cells. Figure S2: High concentrations of cannabinoids inhibit the growth of HPV positive HNSCC cells. Figure S3: Inhibition of CNR1 and CNR2 attenuates the effect of CNR1 / CNR2 agonists on HPV positive HNSCC cells proliferation. Figure S4: CNR1 and CNR2 agonists or antagonists affect the migration of HPV positive HNSCC cells. Figure S5: Cannabinoid receptor agonist activates p38 MAPK pathway. Figure S6: Inhibition of p38 MAPK attenuates the effect of CNR1 / CNR2 agonists on HPV positive HNSCC cells proliferation. Figure S7: Expression of CNR1 and CNR2 in inducible shRNA stably transfected UM-SCC-47 cells. Figure S8: Survival between patients with and without cannabinoids exposure. Figure S9: Gene set enrichment analysis.
Table S2 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Authors: Zhang Jiajun , Liu Weihai , Zou Changye , Zhao Zhiqiang , Lai Yuanying , Shi Zhi , Xie Xianbiao , Huang Gang , Wang Yongqian , Zhang Xuelin , Fan Zepei , Su Qiao , Yin Junqiang , Shen Jingnan
Published: April 2023

Gene expression microarray data of U2-OS and SJSA-1 treated with DMSO or THZ2.
SUPPLEMENTARY MATERIALS AND METHODS from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
Authors: Alemany Regina , Moura David S. , Redondo Andres , Martinez-Trufero Javier , Calabuig Silvia , Saus Carlos , Obrador-Hevia Antonia , Ramos Rafael , Villar Victor H. , Valverde Claudia , Vaz Maria Angeles , Medina Javier , Felipe-Abrio Irene , Hindi Nadia , Taron Miguel , Martin-Broto Javier
Published: April 2023

Pre-Clinical studies and Phase I clinical study supplementary methods.
Supplementary Data from Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma
Authors: Zhang Yiru , Ishida Chiaki Tsuge , Ishida Wataru , Lo Sheng-Fu L. , Zhao Junfei , Shu Chang , Bianchetti Elena , Kleiner Giulio , Sanchez-Quintero Maria J. , Quinzii Catarina M. , Westhoff Mike-Andrew , Karpel-Massler Georg , Canoll Peter , Siegelin Markus D.
Published: April 2023

Supplementary Data
Table S2 from Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials
Authors: Terbuch Angelika , Tiu Crescens , Candilejo Irene Moreno , Scaranti Mariana , Curcean Andra , Bar Dan , Estevez Timon Miriam , Ameratunga Malaka , Ang Joo Ern , Ratoff Jonathan , Minchom Anna R. , Banerji Udai , de Bono Johann S. , Tunariu Nina , Lopez Juanita S.
Published: April 2023

Table S2. DILD Characteristics
Supplementary data from Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability
Authors: Yang Hailing , Mao Weiqun , Rodriguez-Aguayo Cristian , Mangala Lingegowda S. , Bartholomeusz Geoffrey , Iles Lakesla R. , Jennings Nicholas B. , Ahmed Ahmed Ashour , Sood Anil K. , Lopez-Berestein Gabriel , Lu Zhen , Bast Robert C.
Published: April 2023

Table S1. Cell lines and culture media Table S2. GE Dharmacon siRNA catalogues Table S3. Primers Table S4. siRNA transfection conditions for custom screens Table S5. Antibodies for Western blot and immunohistochemistry Table S6. Paclitaxel sensitivity in 12 ovarian cancer cell lines. Table S7. Paclitaxel sensitivity of two siRNA combination in six ovarian cancer cell lines. Table S8. TMA patient information Figure S1. Effects of single kinase siRNA on microtubule stability. Figure S2. Knockdown efficiency was examined in SKOv3ip cells. Figure S3. Sequential treatment of siIKBKB followed by siSTK39 or siEDN2 followed by siTBK1 increases microtubule stability. Figure S4. Sequential treatment of siIKBKB followed by siSTK39 or siEDN2 followed by siTBK1 increases microtubule stability and increasing microtubule stability by depletion of IKBKB/STK39 or EDN2/TBK1 is dependent upon p38-mdiated phosphorylation MAP4. Figure S5. Increasing paclitaxel sensitivity by depletion of IKBKB and TK39 or EDN2 and TBK1 is dependent upon MAP4. Figure S6. Mice tolerate the siRNA and paclitaxel treatment.
Supplementary Table S6 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Table S6
Supplementary Figure 3 from Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Authors: Marciscano Ariel E. , Ghasemzadeh Ali , Nirschl Thomas R. , Theodros Debebe , Kochel Christina M. , Francica Brian J. , Muroyama Yuki , Anders Robert A. , Sharabi Andrew B. , Velarde Esteban , Mao Wendy , Chaudhary Kunal R. , Chaimowitz Matthew G. , Wong John , Selby Mark J. , Thudium Kent B. , Korman Alan J. , Ulmert David , Thorek Daniel L.J. , DeWeese Theodore L. , Drake Charles G.
Published: April 2023

Quantitative analysis of radiation-induced intratumoral chemokine and cytokine expression over time.
Supplementary Figure 2 from Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Authors: Marciscano Ariel E. , Ghasemzadeh Ali , Nirschl Thomas R. , Theodros Debebe , Kochel Christina M. , Francica Brian J. , Muroyama Yuki , Anders Robert A. , Sharabi Andrew B. , Velarde Esteban , Mao Wendy , Chaudhary Kunal R. , Chaimowitz Matthew G. , Wong John , Selby Mark J. , Thudium Kent B. , Korman Alan J. , Ulmert David , Thorek Daniel L.J. , DeWeese Theodore L. , Drake Charles G.
Published: April 2023

Multi-parametric flow cytometry gating schemas
Supplementary Figure 1 from Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Authors: Marciscano Ariel E. , Ghasemzadeh Ali , Nirschl Thomas R. , Theodros Debebe , Kochel Christina M. , Francica Brian J. , Muroyama Yuki , Anders Robert A. , Sharabi Andrew B. , Velarde Esteban , Mao Wendy , Chaudhary Kunal R. , Chaimowitz Matthew G. , Wong John , Selby Mark J. , Thudium Kent B. , Korman Alan J. , Ulmert David , Thorek Daniel L.J. , DeWeese Theodore L. , Drake Charles G.
Published: April 2023

Radiation plan dosimetry and dose-volume histograms
Supplementary Data from CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer
Authors: Faisal Farzana A. , Murali Sanjana , Kaur Harsimar , Vidotto Thiago , Guedes Liana B. , Salles Daniela Correia , Kothari Vishal , Tosoian Jeffrey J. , Han Sumin , Hovelson Daniel H. , Hu Kevin , Spratt Daniel E. , Baras Alexander S. , Tomlins Scott A. , Schaeffer Edward M. , Lotan Tamara L.
Published: April 2023

Supplementary Tables S1-S5
Table S4 from Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression
Authors: Marcon Julian , DiNatale Renzo G. , Sanchez Alejandro , Kotecha Ritesh R. , Gupta Sounak , Kuo Fengshen , Makarov Vladimir , Sandhu Amar , Mano Roy , Silagy Andrew W. , Blum Kyle A. , Nassau Daniel E. , Benfante Nicole E. , Ortiz Michael V. , Carlo Maria I. , Chan Timothy A. , Motzer Robert J. , Voss Martin H. , Coleman Jonathan , Russo Paul , Reuter Victor , Hakimi A. Ari , Reznik Ed
Published: April 2023

Table S4 contains a list of copy number events on the arm level of MSK-IMPACT and TCGA cohorts
Supplementary information from Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis
Authors: Liu Sijia , González-Prieto Román , Zhang Mengdi , Geurink Paul P. , Kooij Raymond , Iyengar Prasanna Vasudevan , van Dinther Maarten , Bos Erik , Zhang Xiaobing , Le Dévédec Sylvia E. , van de Water Bob , Koning Roman I. , Zhu Hong-Jian , Mesker Wilma E. , Vertegaal Alfred C.O. , Ovaa Huib , Zhang Long , Martens John W.M. , ten Dijke Peter
Published: April 2023

Supplementary methods, supplementary table legends, supplementary references.
Table S2 from Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression
Authors: Marcon Julian , DiNatale Renzo G. , Sanchez Alejandro , Kotecha Ritesh R. , Gupta Sounak , Kuo Fengshen , Makarov Vladimir , Sandhu Amar , Mano Roy , Silagy Andrew W. , Blum Kyle A. , Nassau Daniel E. , Benfante Nicole E. , Ortiz Michael V. , Carlo Maria I. , Chan Timothy A. , Motzer Robert J. , Voss Martin H. , Coleman Jonathan , Russo Paul , Reuter Victor , Hakimi A. Ari , Reznik Ed
Published: April 2023

Table S2 shows clinical and genomic metadata of MSK-IMPACT and TCGA cohorts
Supplementary Figure S5 from Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis
Authors: Liu Sijia , González-Prieto Román , Zhang Mengdi , Geurink Paul P. , Kooij Raymond , Iyengar Prasanna Vasudevan , van Dinther Maarten , Bos Erik , Zhang Xiaobing , Le Dévédec Sylvia E. , van de Water Bob , Koning Roman I. , Zhu Hong-Jian , Mesker Wilma E. , Vertegaal Alfred C.O. , Ovaa Huib , Zhang Long , Martens John W.M. , ten Dijke Peter
Published: April 2023

Supplementary Figure S5. Related to Figure 4. A, Real-time scratch assay of MDA-MB-231 cells that are engineered to overexpressed TÎ²RI, SMAD2 or SMAD3 using the IncuCyte system. Western blot analysis of TÎ²RI, SMAD2 or SMAD3 expression levels in MDA-MB-231 cells (above). Representative scratch wound results at the end time point of the experiment are shown (middle). The region of the original scratch is colored in purple and the area of cell migration into the scratch is colored in yellow. Relative wound density (closure) is plotted at indicate times (below). ****, P < 0.0001, two-way analysis of variance (ANOVA). Same blot was used for TÎ²RI and GAPDH (loading control). UCHL1 and SMAD2/3 results were derived from another blot using the same corresponding cell lysates. B, Real-time scratch assay of MDA-MB-436 shUCHL1 cells that are engineered to overexpressed TÎ²RI, SMAD2 or SMAD3 using the IncuCyte system. Western blot of TÎ²RI, SMAD2 or SMAD3 expression levels in MDA-MB-436 shUCHL1 cells (above). Representative scratch wound results at the end time point of the experiment are shown (middle). Relative wound density (closure) is plotted at indicate times (below). **, P < 0.01, ****, P < 0.0001, two-way analysis of variance (ANOVA). Same blot was used for TÎ²RI and GAPDH (loading control). UCHL1 and SMAD2/3 levels in corresponding cell lysates were determined using another blot. C, Real-time scratch assay of MDA-MB-231 cells that overexpress with UCHL1 WT or UCHL1 C90A using the IncuCyte system. Representative scratch wound results at the end time point of the experiment are shown (above). Relative wound density (closure) is plotted at indicate times (below). ***, P < 0.001, ****, P < 0.0001, two-way analysis of variance (ANOVA). D, In vivo zebrafish extravasation assay of MDA-MB-231 cells that overexpress UCHL1 WT or UCHL1 C90A. Representative images of zebrafish tail fin with zoom in of invasive cells (above). Analysis of invasive cell numbers of control, UCHL1 WT and UCHL1 C90A groups in zebrafish extravasation experiment (below). **, P < 0.01, ****, P < 0.0001, two-way analysis of variance (ANOVA).
Supplemental Table 1 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Authors: Aggarwal Charu , Thompson Jeffrey C. , Chien Austin L. , Quinn Katie J. , Hwang Wei-Ting , Black Taylor A. , Yee Stephanie S. , Christensen Theresa E. , LaRiviere Michael J. , Silva Benjamin A. , Banks Kimberly C. , Nagy Rebecca J. , Helman Elena , Berman Abigail T. , Ciunci Christine A. , Singh Aditi P. , Wasser Jeffrey S. , Bauml Joshua M. , Langer Corey J. , Cohen Roger B. , Carpenter Erica L.
Published: April 2023

Mutations Analyzed
Supplemental Figure 3 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Authors: Aggarwal Charu , Thompson Jeffrey C. , Chien Austin L. , Quinn Katie J. , Hwang Wei-Ting , Black Taylor A. , Yee Stephanie S. , Christensen Theresa E. , LaRiviere Michael J. , Silva Benjamin A. , Banks Kimberly C. , Nagy Rebecca J. , Helman Elena , Berman Abigail T. , Ciunci Christine A. , Singh Aditi P. , Wasser Jeffrey S. , Bauml Joshua M. , Langer Corey J. , Cohen Roger B. , Carpenter Erica L.
Published: April 2023

pTMBand PD-L1 expression levels.
Supplementary Figures and Tables from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Authors: Sanai Nader , Li Jing , Boerner Julie , Stark Karri , Wu Jianmei , Kim Seongho , Derogatis Alanna , Mehta Shwetal , Dhruv Harshil D. , Heilbrun Lance K. , Berens Michael E. , LoRusso Patricia M.
Published: April 2023

Supplementary Figures and Tables
Table S3 from Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics
Authors: Xing Deyin , Zheng Gang , Pallavajjala Aparna , Schoolmeester J. Kenneth , Liu Yuehua , Haley Lisa , Hu Yan , Liu Li , Logan Lisa , Lin Yuan , Pearce Kathryn E. , Sattler Christopher A. , Tsai Ya Chea , Vang Russell , Hung Chien-Fu , Wu T.-C. , Ronnett Brigitte M.
Published: April 2023

Supplementary Table S3
Supplementary Appendix, Figures, Tables from Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials
Authors: Yuan Ying , Lin Ruitao , Li Daniel , Nie Lei , Warren Katherine E.
Published: April 2023

Supplementary Appendix A-D, Tables 1-3, Figures 1-10
Figure S2 from Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy
Authors: Yang Linlin , Shen Changxian , Pettit Cory J. , Li Tianyun , Hu Andrew J. , Miller Eric D. , Zhang Junran , Lin Steven H. , Williams Terence M.
Published: April 2023

Comparable colony numbers between cells with or without AZD1775 treatment suggests 100 nM AZD1775 has minimal cell cytotoxicity on cells. OE33, SK4, FLO1 and KYSE cells were cultured in media containing 100 nM AZD1775 and subjected to clonogenic survival assay. Each dose was prepared in triplicate per experiment, and no less than 2 experiments were performed per cell line.
Figure S1 from Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Authors: Hargrave Darren R. , Bouffet Eric , Tabori Uri , Broniscer Alberto , Cohen Kenneth J. , Hansford Jordan R. , Geoerger Birgit , Hingorani Pooja , Dunkel Ira J. , Russo Mark W. , Tseng Lillian , Dasgupta Kohinoor , Gasal Eduard , Whitlock James A. , Kieran Mark W.
Published: April 2023

Trial design
Supplementary Data from Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors
Authors: Llosa Nicolas J. , Luber Brandon , Tam Ada J. , Smith Kellie N. , Siegel Nicholas , Awan Anas H. , Fan Hongni , Oke Teniola , Zhang JiaJia , Domingue Jada , Engle Elizabeth L. , Roberts Charles A. , Bartlett Bjarne R. , Aulakh Laveet K. , Thompson Elizabeth D. , Taube Janis M. , Durham Jennifer N. , Sears Cynthia L. , Le Dung T. , Diaz Luis A. , Pardoll Drew M. , Wang Hao , Anders Robert A. , Housseau Franck
Published: April 2023

supplementary methods, tables and figures Supplementary Table S1. Demographics of patients from clinical trial NCT01876511 Supplementary Table S2. Demographics of untreated CRC patients Supplementary Table S3. Target genes and specific primer/probes gene expression assay used for Taqman PCR Supplementary Table S4. Summary statistics of immune related gene expression between responder (R) and non-responder (NR) mCRC treated with pembrolizumab, sorted by Wilcoxon-Mann Whitney p-value Supplementary Table S5. Significant p values (p<0.05) of gene expression between newly defined R-type and NR-type MMRp specimens. Supplementary Table S6. Summary statistics for paired differences of gene expression between cell-sorted CD8+ PD1hi and CD8+ PD1lo TILs of resected primary CRC. Gene expression in PD1hi and PD1lo were relative to expression in PD1neg CD8+ TILs (ï�„ï�„Ct). Supplementary Table S7. Th1 and mixed Th1/Th17 immune signatures in MSS samples extracted from TCGA database Supplementary Figure S1. Model of TiME in primary colon tumor of mCRC patients according to their clinical response to pembrolizumab. Supplementary Figure S2. IFNï�§-producing PD1hi CD8+ T cells are not detected in the distal normal colon tissue. Supplementary Figure S3. Cell-sorted PD1hiCD8+ TIL in CRC are exhausted T cells. Supplementary figure S4. MSI high MMRd CRC 3784 TIL includes only few IFNï�§+PD1hi CD4+ or CD8+ T cells. Supplementary Figure S5. Gene expression analysis in conventional MMRp, type 1 immunoreactive MMRp and type 17 immunoreactive MMRp colon tumors. Supplementary Figure S6. IHC staining on type 17 immunoreactive MMRp CRC. Supplementary Figure S7. IHC staining on conventional MMRp CRC. Supplementary Figure S8. Correlation between the PD-L1 expression in IF of primary colon tumors and the proportion of Th1 and Th17 in TILs. Supplementary Figure S9. CD3 and CD8 cells quantification by IHC and tumor mutation numbers in untreated resected primary CRC lesion. Supplementary Figure S10. Detection of Type 1 and Type 17 immunoreactive MMRp CRC samples in TCGA database.
Table S5 from Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma
Authors: Piano Maria Assunta , Brunello Antonella , Cappellesso Rocco , Del Bianco Paola , Mattiolo Adriana , Fritegotto Chiara , Montini Barbara , Zamuner Carolina , Del Fiore Paolo , Rastrelli Marco , Sommariva Antonio , De Salvo Gian Luca , Montesco Maria Cristina , Rossi Carlo Riccardo , Zagonel Vittorina , Calabrò Maria Luisa
Published: April 2023

STR profile of the primary sarcoma cell lines.
Supplementary Table and Figure from Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
Authors: Gupta Shilpa , Nordquist Luke T. , Fleming Mark T. , Berry William R. , Zhang Jingsong , Ervin Sharon L. , Eisner Joel R. , Baskin-Bey Edwina S. , Shore Neal D.
Published: April 2023

Supplemental Table 1: Overview of Treatment Duration, Discontinuations and Dose Modifications Supplemental Figure 1: Seviteronel Plasma Concentrations over Time - Single Dose.
Table S2 from Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma
Authors: Piano Maria Assunta , Brunello Antonella , Cappellesso Rocco , Del Bianco Paola , Mattiolo Adriana , Fritegotto Chiara , Montini Barbara , Zamuner Carolina , Del Fiore Paolo , Rastrelli Marco , Sommariva Antonio , De Salvo Gian Luca , Montesco Maria Cristina , Rossi Carlo Riccardo , Zagonel Vittorina , Calabrò Maria Luisa
Published: April 2023

Univariate and multiple Cox regression models for clinical predictors of OS.
Figure S3 from Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma
Authors: Piano Maria Assunta , Brunello Antonella , Cappellesso Rocco , Del Bianco Paola , Mattiolo Adriana , Fritegotto Chiara , Montini Barbara , Zamuner Carolina , Del Fiore Paolo , Rastrelli Marco , Sommariva Antonio , De Salvo Gian Luca , Montesco Maria Cristina , Rossi Carlo Riccardo , Zagonel Vittorina , Calabrò Maria Luisa
Published: April 2023

Characterization of primary sarcoma cell lines.
Figure S2 from Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma
Authors: Piano Maria Assunta , Brunello Antonella , Cappellesso Rocco , Del Bianco Paola , Mattiolo Adriana , Fritegotto Chiara , Montini Barbara , Zamuner Carolina , Del Fiore Paolo , Rastrelli Marco , Sommariva Antonio , De Salvo Gian Luca , Montesco Maria Cristina , Rossi Carlo Riccardo , Zagonel Vittorina , Calabrò Maria Luisa
Published: April 2023

Kaplan-Meier curves for OS of STS patients of the screening set.
Supplementary Data Figure 2 from Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
Authors: Matuszewska Kathy , Santry Lisa A. , van Vloten Jacob P. , AuYeung Amanda W.K. , Major Pierre P. , Lawler Jack , Wootton Sarah K. , Bridle Byram W. , Petrik Jim
Published: April 2023

Supplementary Data Figure 2 Supplementary Data, Figure 2. ID8, CAOV-3 and NOSE cells were infected or mock infected (1x PBS) at an MOI of 0.1. Infected and uninfected cells were collected 24 hours later and stained for Annexin V a marker for early apoptosis and 7-Aminoactinomycin D (7AAD) a marker for dead cells (N=3). A, The cytogram of the four quadrants was used to distinguish normal (Annexin Vâ^'/7AAD+), early apoptotic (Annexin V+/7AADâ^'), late apoptotic (Annexin V+/7AAD+), and necrotic cells (Annexin Vâ^'/7AAD+). B, The sum of early and late apoptosis was presented as total apoptosis. Means +/- SEM are shown. Data were analyzed by 2way analysis of variance with Sidak's multiple comparison test; **,P<0.01 (N=3).
Figure S5 from ΔNp63γ/SRC/Slug Signaling Axis Promotes Epithelial-to-Mesenchymal Transition in Squamous Cancers
Authors: Srivastava Kirtiman , Pickard Adam , Craig Stephanie G. , Quinn Gerard P. , Lambe Shauna M. , James Jacqueline A. , McDade Simon S. , McCance Dennis J.
Published: April 2023

Figure S5 shows (A) venn diagram comparing E6/E7-HFK TP63 ChIP-seq peaks with published normal HFK TP63 ChIP-seq (McDade et al, 2014) (B) Visualisation of E6/E7 and normal HFK TP63 ChIP-seq tracks around CDH1 loci annotated with Encode histone modification data from normal human epidermal keratinocytes (NHEK) (Myers et al, 2011).
Figure S1-S17 from The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas
Authors: Huang Manling , He Minghui , Guo Yu , Li Heping , Shen Shunli , Xie Yubin , Li Xiaoxing , Xiao Han , Fang Lujing , Li Dongming , Peng Baogang , Liang Lijian , Yu Jun , Kuang Ming , Xu Lixia , Peng Sui
Published: April 2023

Fig.S1 shows flow chart of enrollment for multifocal HCC patients with anti-PD-1 therapy. Fig.S2 shows CT images of the six HCC patients with two tumors in the liver. Fig.S3 shows purity of tumor content of the six HCC patients with two tumors in the liver. Fig.S4 shows HBV integration sites in the six HCC patients with two tumors in the liver. Fig.S5 shows expression level of TERT in the six HCC patients with two tumors in the liver. Fig.S6 shows landscape of inter-chromosomal translocations and copy number alterations in small and large tumors of four cases. Fig.S7 shows number and types of chromosomal rearrangement in the six HCC patients with two tumors in the liver. Fig.S8 shows copy number aberrations in the six HCC patients with two tumors in the liver. Fig.S9 shows mutational landscape of the six HCC patients with two tumors in the liver. Fig.S10 shows non-silent mutations in the six HCC patients with two tumors in the liver. Fig.S11 shows profile of mutational cancer cell fractions of small and large tumors in the six HCC patients. Fig.S12 shows unsupervised clustering of RNA expression in tumors and adjacent normal liver tissues of 12 multifocal HCC patients. Fig.S13 shows expression level of immune functional genes in small and large tumors of 12 multifocal HCC patients. Fig.S14 shows expression level of immune stimulators in small and large tumors of 12 multifocal HCC patients. Fig.S15 shows expression level of immune inhibitors in small and large tumors of 12 multifocal HCC patients. Fig.S16 shows mutations of immune-related genes in the six HCC patients with two tumor nodules in the liver. Fig.S17 shows images of the small and large tumors before and after anti-PD-1 therapy.
Figure S6 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Fig.6: The effect of PD-L1 expression by inactivation of MAN2A1.
Figure S4 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Fig.4: The effect of Man2a1 knockout on the IFN-γ downstream activation and cytokine sensitivity.
Supplementary Sheet from Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma
Authors: Beig Niha , Bera Kaustav , Prasanna Prateek , Antunes Jacob , Correa Ramon , Singh Salendra , Saeed Bamashmos Anas , Ismail Marwa , Braman Nathaniel , Verma Ruchika , Hill Virginia B. , Statsevych Volodymyr , Ahluwalia Manmeet S. , Varadan Vinay , Madabhushi Anant , Tiwari Pallavi
Published: April 2023

Supplementary Sheet
Figure S1 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Fig.1: The association between the CTL level and overall patient survival.
Supplementary Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma
Authors: Chawla Sant P. , Goel Sanjay , Chow Warren , Braiteh Fadi , Singh Arun S. , Olson Juneko E. Grilley , Osada Atsushi , Bobe Iulian , Riedel Richard F.
Published: April 2023

Table S1. shows progression Free Survival in individual subjects. Table S2. show exposures to epirubicinol in subjects who received infusion of NC-6300. Figure S1. shows total epirubicin concentrations (mean {plus minus} SD) at the end of infusion of 170 mg/m2 NC-6300 across cycles. Figure S2. shows mean Change in EORTC QLQ-C30 Score from Baseline.
Figure S1 from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma
Authors: Chawla Sant P. , Goel Sanjay , Chow Warren , Braiteh Fadi , Singh Arun S. , Olson Juneko E. Grilley , Osada Atsushi , Bobe Iulian , Riedel Richard F.
Published: April 2023

Figure S1. shows total epirubicin concentrations (mean {plus minus} SD) at the end of infusion of 170 mg/m2 NC-6300 across cycles.
Supplementary Figure 2 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Authors: Balmanoukian Ani S. , Infante Jeffrey R. , Aljumaily Raid , Naing Aung , Chintakuntlawar Ashish V. , Rizvi Naiyer A. , Ross Helen J. , Gordon Michael , Mallinder Philip R. , Elgeioushi Nairouz , González-García Ignacio , Standifer Nathan , Cann Jennifer , Durham Nicholas , Rahimian Shahram , Kumar Rakesh , Denlinger Crystal S.
Published: April 2023

Changes in peripheral GITR+ effector memory T-cells from baseline were measured in the 25 mg, 75 mg, 250 mg, and 500 mg cohorts.
Supplementary Table 1 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Authors: Poschke Isabel C. , Hassel Jessica C. , Rodriguez-Ehrenfried Aaron , Lindner Katharina A.M. , Heras-Murillo Ignacio , Appel Lena M. , Lehmann Johanna , Lövgren Tanja , Wickström Stina L. , Lauenstein Claudia , Roth Jasmin , König Anna-Katharina , Haanen John B.A.G. , van den Berg Joost , Kiessling Rolf , Bergmann Frank , Flossdorf Michael , Strobel Oliver , Offringa Rienk
Published: April 2023

Supplementary Table 1
Supplementary Table S1 from Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors
Authors: Sanfilippo Roberta , Fabbroni Chiara , Fucà Giovanni , Fumagalli Elena , Morosi Carlo , Sbaraglia Marta , Gronchi Alessandro , Collini Paola , Dei Tos Angelo P. , Casali Paolo G.
Published: April 2023

Prior systemic treatments for advanced disease and clinicoradiological outcomes to the previous line of treatment with mTOR inhibitor alone.
Supplementary Figure S1 from Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors
Authors: Sanfilippo Roberta , Fabbroni Chiara , Fucà Giovanni , Fumagalli Elena , Morosi Carlo , Sbaraglia Marta , Gronchi Alessandro , Collini Paola , Dei Tos Angelo P. , Casali Paolo G.
Published: April 2023

Kaplan-Meier curve for PFS of the previous treatment with mTOR inhibitor alone.
Figure S7 from Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
Authors: Truong Amanda , Yoo Jae Hyuk , Scherzer Michael T. , Sanchez John Michael S. , Dale Kali J. , Kinsey Conan G. , Richards Jackson R. , Shin Donghan , Ghazi Phaedra C. , Onken Michael D. , Blumer Kendall J. , Odelberg Shannon J. , McMahon Martin
Published: April 2023

YAP activation in OMM1 cells
Figure S3 from Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
Authors: Truong Amanda , Yoo Jae Hyuk , Scherzer Michael T. , Sanchez John Michael S. , Dale Kali J. , Kinsey Conan G. , Richards Jackson R. , Shin Donghan , Ghazi Phaedra C. , Onken Michael D. , Blumer Kendall J. , Odelberg Shannon J. , McMahon Martin
Published: April 2023

Response of uveal melanoma cell lines to MEK1/2 inhibition
Supplementary Data from Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma
Authors: Yadav Siddhartha , Kasi Pashtoon M. , Bamlet William R. , Ho Thanh P. , Polley Eric C. , Hu Chunling , Hart Steven N. , Rabe Kari G. , Boddicker Nicholas J. , Gnanaolivu Rohan D. , Lee Kun Y. , Lindstrom Tricia H. , Petersen Gloria M. , Couch Fergus J. , McWilliams Robert R.
Published: April 2023

Genomic data/details, additional analyses
Supplementary Figure 3 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Authors: Gray Katherine D. , McCloskey Jaclyn E. , Vedvyas Yogindra , Kalloo Olivia R. , Eshaky Steve El , Yang Yanping , Shevlin Enda , Zaman Marjan , Ullmann Timothy M. , Liang Heng , Stefanova Dessislava , Christos Paul J. , Scognamiglio Theresa , Tassler Andrew B. , Zarnegar Rasa , Fahey Thomas J. , Jin Moonsoo M. , Min Irene M.
Published: April 2023

PD1 inhibition enhances survival benefit of CAR T treatment in KHM-5M xenografts.
Supplementary Figure 2 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Authors: Gray Katherine D. , McCloskey Jaclyn E. , Vedvyas Yogindra , Kalloo Olivia R. , Eshaky Steve El , Yang Yanping , Shevlin Enda , Zaman Marjan , Ullmann Timothy M. , Liang Heng , Stefanova Dessislava , Christos Paul J. , Scognamiglio Theresa , Tassler Andrew B. , Zarnegar Rasa , Fahey Thomas J. , Jin Moonsoo M. , Min Irene M.
Published: April 2023

Characteristics of each donor leukopak used in in vivo study.
Supplementary Methods from DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas
Authors: Weidema Marije E. , van de Geer Ellen , Koelsche Christian , Desar Ingrid M.E. , Kemmeren Patrick , Hillebrandt-Roeffen Melissa H.S. , Ho Vincent K.Y. , van der Graaf Winette T.A. , Versleijen-Jonkers Yvonne M.H. , von Deimling Andreas , Flucke Uta E.
Published: April 2023

Supplementary Methods: DNA methylation calculation and bootstrapping method
Supplement 1 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
Authors: Fenk Roland , Giagounidis Aristoteles , Goldschmidt Hartmut , Heinsch Michael , Rummel Mathias , Kroger Nicolaus , Boquoi Amelie , Lopez David , Gerrlich Celina , Baier Julia , Liesenjohann Svenja , Hauck Katarzyna , Savickaite Ingrida , Mai Elias K. , Aul Carlo , Strapatsas Judith , Dienst Ariane , Kondakci Mustafa , Haas Rainer , Kobbe Guido
Published: April 2023

Centers and enrolment